We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Wireless Connectivity Transforms POC Blood Glucose Testing

By LabMedica International staff writers
Posted on 07 Jul 2011
The National Health Service (NHS; United Kingdom) Trust has installed wireless blood glucose meters in wards, clinics, and theaters across all three of its acute hospital sites in Mid Yorkshire (United Kingdom).

Wireless devices, connected by intelligent IT systems are vital for patient safety and for meeting Clinical Pathology Accreditation (CPA) requirements for Point of Care (POC) testing.

The meters are linked wirelessly to the Hospital Information System (HIS) via the Roche POC data management solution, cobas IT 1000, allowing them to be managed centrally in accordance with national guidelines for POC devices.

In addition to transmitting patient results, Roche Diagnostic's (Burgess Hill, United Kingdom) blood glucose meter, Accu-Chek Inform II records quality control (QC) results, operator and patient details, consumable details, configuration information, and comments. More...
The data transmitted by the meters is managed by cobas IT 1000, which permits patient validation, operator recognition, and material lot tracking.

“Our new blood glucose testing system helps us to fulfill CPA requirements in a number of ways,” explained Tracey Eastwood, senior BMS responsible for POC testing within the Trust. “It provides a central record of all data, including QC records, which, in turn, provide an important audit trail. The system also enables us to manage reagents, calibrations, and quality control centrally. Centralized calibration of glucose meters has removed the risk of operator errors and the QC lockout feature ensures that operators perform the necessary QC activities at the required intervals, otherwise the meter cannot be used.”

While there is no cure for diabetes at the moment, management of the disease has become more effective.

Related Links:

National Health Service
Roche Diagnostics



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.